CareLit · DOI-Nachweis · Pneumologie
Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgr…
DOI 10.1055/s-0039-3403159
Bibliografische Angaben
Nachweis in CareLit
Autor:innenFJ Martinez, GT Ferguson, E Bourne, S Ballal, P Darken, K DeAngelis, M Aurivillius, P Dorinsky, C Reisner
ZeitschriftPneumologie
AusgabeS 01 S 01/2020
Jahrgang / SeitenJg. 74
Kernaussage aus der Literatur
Abstract-Vorschau
Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgroup analysis of KRONOS study
Zitieren
Zitierempfehlung
FJ Martinez, GT Ferguson, E Bourne, S Ballal, P Darken, K DeAngelis, M Aurivillius, P Dorinsky, C Reisner (2020) Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgroup analysis of KRONOS study. Pneumologie, 74 (S 01 S 01). https://doi.org/10.1055/s-0039-3403159
Mit CareLit weiterarbeiten